Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...
Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...
Sanofi is gearing up for another major sports sponsorship in its home country, this time with the 2027 Tour de France. | The ...
In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...
Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...
Roche extended its China shopping spree with a $1 billion-plus obesity deal. | Roche extended its China shopping spree with a ...
U.S.-based generic drugmaker Par Health has issued a voluntary recall of 22 lots of the direct thrombin inhibitor argatroban ...
In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...
Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...
Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...
With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...
Expanding its presence in dermatology, Cetaphil maker Galderma has agreed to acquire professional skincare shop Zo Skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results